VERAXA Biotech
PrivateLast Round
M&A
Apr 22, 2025
Est. Valuation
$1.64B
Total Funding Raised
$3.41M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
VERAXA Biotech is a biotechnology company developing next-generation antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and T-cell engagers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VERAXA Biotech Comparables
Compare VERAXA Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CytomX Therapeutics | 87% | |
| Eli Lilly and Company | 79% | |
| Zymeworks Inc. | 78% |
VERAXA Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Apr 22, 2025 | ||||
| Series B | Jun 27, 2019 |
VERAXA Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EMBLEM Technology Transfer | M&A, Series B |
| European Molecular Biology Laboratory | M&A, Series B |
| Xlife Sciences AG | M&A, Series B |
| Voyager Acquisition Corp. | M&A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 15, 35% of headcount.
- Jul 13, 2026
Open roles increased to 13, 5.2x the trailing average.
Recent news
Latest coverage and updates
- hiresSep 4, 2026
VERAXA Biotech GmbH hired Raju Willener as chief financial officer on Sep 4th '26.
- is_developingAug 28, 2026
VERAXA Biotech GmbH is developing antibody oligonucleotide conjugates on Aug 24th '26.
- is_developingAug 27, 2026
VERAXA Biotech GmbH is developing bispecific ADC for solid tumors on May 1st '25.
- integrates_withAug 24, 2026
VERAXA Biotech GmbH integrates with Secarna Pharmaceuticals GmbH.
- is_developingAug 24, 2026
VERAXA Biotech GmbH is developing antibody-based cancer therapies on Aug 24th '26.
VERAXA Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about VERAXA Biotech's valuation, stock price, and market status.
Is VERAXA Biotech a public or private company?
VERAXA Biotech is a private company.
What is the current stock price of VERAXA Biotech?
VERAXA Biotech is a private company with no public stock price. No recent secondary market data is available.
How much is VERAXA Biotech worth (valuation)?
VERAXA Biotech's valuation is estimated at $1.6B based on funding round data.
Can I buy VERAXA Biotech stock?
VERAXA Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was VERAXA Biotech's last funding round?
VERAXA Biotech's most recent funding round was M&A on April 22, 2025.
Who are the main investors in VERAXA Biotech?
Key investors in VERAXA Biotech include EMBLEM Technology Transfer, European Molecular Biology Laboratory, Xlife Sciences AG, Voyager Acquisition Corp..
Will VERAXA Biotech IPO soon?
No public IPO plans have been announced for VERAXA Biotech.
How can I track VERAXA Biotech secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VERAXA Biotech's secondary market activity and sign up for updates.